The combined inhibition of PD-1/PD-L1 with TGFß receptor kinase inhibitors has also been shown to enhance tumor regression in preclinical tumor models51,52 and a bifunctional fusion protein targeting PD-L1 and TGFß in solid tumors showed encouraging efficacy in a recent Phase I trial53. Here, PDCD1 is linked to neoplasm.